Top Markets
#1 MowCat MowCat +48.96%
#2 Velvet Velvet +32.75%
#3 Audiera Audiera +25.14%
#4 Derive Derive +19.55%
#5 Quack AI Quack AI +17.50%
#6 Biconomy Biconomy +15.21%
#7 aPriori aPriori +14.35%
#8 Cross Cross +12.67%
#9 Humanity Humanity +11.35%
#10 Geodnet Geodnet +10.81%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Rhinomed Limited Rhinomed Limited

Rhinomed Limited

RNO
Rank in Stocks #35584
Headquartered in Cremorne, Australia, Rhinomed Limited is a global enterprise... Headquartered in Cremorne, Australia, Rhinomed Limited is a global enterprise dedicated to the research, development, and market introduction of consumer and medical devices. Since its incorporation in 2004, the company has focused on creating wearable nasal technologies designed to optimize breathing, improve sleep quality, support general health, and assist in disease diagnosis. Its product offerings include the Turbine, which enhances athletic breathing; Mute, aimed at reducing snoring and promoting clearer airflow; Pronto, a vapor inhaler developed to aid airflow and sleep; and Rhinoswab, utilized for efficient nasal sample collection. Beyond these products, Rhinomed is actively engaged in developing programs across diverse fields such as sleep architecture, the cognitive impact of sleep and respiratory function, obstructive sleep apnea, pain and nausea relief, respiratory diseases, and advanced diagnostics and sensors. The company also provides a distinct drug delivery platform specifically for cannabinoid formulations. Formerly known as Consegna Group Limited, the company adopted the name Rhinomed Limited in November 2013.
Share Price
$0.0260778
Last synced: 2024-02-16
Market Cap
$3.69M
Change (1 day)
-0.09%
Change (1 year)
0.00%
Country
AU
Trade Rhinomed Limited (RNO)

Category

Healthcare
P/E ratio for Rhinomed Limited (RNO)
P/E ratio as of 2026 TTM: 0
According to Rhinomed Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Rhinomed Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.77 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 34.86 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 20.90 -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 52.64 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.